A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy.
about
Clinical applications of transient elastographyNon-invasive diagnosis of hepatitis B virus-related cirrhosisDeterminants for the occurrence of acute exacerbation of hepatitis B virus infection in Chinese patients after HBeAg seroclearance.Natural history of chronic hepatitis B: phases in a complex relationship.Transient elastography in chronic hepatitis B: an Asian perspective.Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals.Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon.Protein profiling in hepatocellular carcinoma by label-free quantitative proteomics in two west African populationsImpact of genetic heterogeneity in polymerase of hepatitis B virus on dynamics of viral load and hepatitis B progression.Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective studyFlares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy.Management of chronic hepatitis B in patients from special populationsHow many valid measurements are necessary to assess liver fibrosis using FibroScan® in patients with chronic viral hepatitis? An analysis of subjects with at least 10 valid measurements.Intrahepatic mRNA Expression of FAS, FASL, and FOXP3 Genes Is Associated with the Pathophysiology of Chronic HCV Infection.Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment.HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis.Cost of treating chronic hepatitis B: comparison of current treatment guidelines.Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response.Prediction of early HBeAg seroconversion by decreased titers of HBeAg in the serum combined with increased grades of lobular inflammation in the liver.Recommendations and potential future options in the treatment of hepatitis B.Revisiting the natural history of chronic hepatitis B: impact of new concepts on clinical management.Molecular testing in the diagnosis and management of chronic hepatitis BEfficacy and safety of a chinese herbal formula (invigorating kidney and strengthening spleen) in chronic hepatitis B virus carrier: results from a multicenter, randomized, double-blind, and placebo-controlled trialDisease burden of chronic hepatitis B among immigrants in Canada.Clinical evaluation of the digene hybrid capture II test and the COBAS AMPLICOR monitor test for determination of hepatitis B virus DNA levelsA combination treatment of entecavir and early-phase corticosteroid in severe exacerbation of chronic hepatitis B.Baseline predictors of virological response for chronic hepatitis B patients.Chronic hepatitis B in Asian women of childbearing age.Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases.Detection of intrahepatic hepatitis B virus DNA and correlation with hepatic necroinflammation and fibrosis.The degrees of hepatocyte cytoplasmic expression of hepatitis B core antigen correlate with histologic activity of liver disease in the young patients with chronic hepatitis B infection.Emerging drugs for the treatment of hepatitis B.Relationship between hepatitis B DNA viral load in the liver and its histology in patients with chronic hepatitis B.Individual prediction model for lamivudine treatment response in hepatitis B virus e antigen-positive chronic hepatitis B patients.Antiviral Therapy in Chronic Hepatitis B With Mild Acute Exacerbation.The role of interleukin-27 in predicting spontaneous HBeAg seroconversion in chronic hepatitis B infection.Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir.Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis.
P2860
Q26828052-A83EFC2C-B1ED-407B-8CB0-DD9D04C1C7ABQ30442641-7B41D606-0152-4807-86BB-A5DD6E2DFCCCQ33753308-EDC40FBF-461C-42C4-91A9-3FF829FAAA68Q34036650-C1242718-23DF-4328-8BF8-B39062F02FE3Q34284732-7B74DE02-BD15-4E8D-92CA-83ECE2DB02CEQ34674838-01D03467-93D5-4B60-B783-2631BDB1E2D7Q34779745-581DD5A2-D703-4F4E-AEDB-35CF554A3340Q34785877-0B243001-CBD1-4F60-8EFE-6E16D1C77125Q34918154-FBC07974-A2DD-43B0-95D4-22183B213C60Q34922094-66F8BB98-1630-4FC1-B501-72FD2C29E86CQ35487430-2B9B8058-0EF0-4CD8-A3BC-35B239A7FA0FQ35597901-55365A75-3E05-4E1A-8AC1-BD781C300ACCQ35664183-9B8B5D21-E714-4E3F-B7E6-1610258674F0Q35767497-5419499B-20F1-4673-B3EE-DF0E59A2EC64Q36034835-CCAC3A79-25DB-401B-8A34-5BBF664CA358Q36180475-EC8D8A53-9896-46AE-9EF3-449BEED84662Q36255419-A0878FE5-84E4-4C23-895A-81C48F45469EQ36395368-7BDD1B59-4479-4924-A51F-D8195A5207C0Q36457659-B37CA4D4-A3F9-40F2-A7B4-183B38A52A48Q36577653-2A32A88F-52C0-47A6-9765-5D598AEE9408Q36632233-44BD2E39-E4A4-4810-9EFC-40841C43DF46Q36816153-43BF13C0-8F02-4340-9F48-5056B27CB655Q36881140-1B2D11A2-3238-4F07-BCA7-D00AF51520B4Q37043981-66A8B977-67B5-4D4B-B39D-70E67A5F8A11Q37066397-207A26F7-A076-41CD-BD27-DF342F2EBE78Q37156183-2C83DA8A-7490-41AB-BBED-BE746FA08033Q37160586-8C964557-EEE9-405C-9E19-45239D5B5C25Q37347347-8ADFCD65-A6CC-49E2-8BC4-415B4F51D91CQ37380063-DEF1FBD0-5C7B-4A93-BA4D-1CE76DB50E97Q37386578-39522196-BE13-4339-A653-887AB679050AQ37511323-3ABB6DA4-FA57-4D78-A9B0-72C1666D47CEQ38510483-9D5A14DA-9493-4E38-8CD7-FC77C437CEE8Q38759805-35135F6E-D63C-4642-894C-5E046D20BCCDQ38908489-0745FFF9-18CF-4D04-B1D6-C85EB2926FEAQ39243598-F3A5C9A4-FC46-4A52-88F5-10ECA9239E7BQ40303523-835878F2-E733-4DEA-AA1B-BACAB05848E9Q40362295-70E0F96B-97D6-4B22-8E1D-801E673BA601Q40433719-F6F65201-5616-4D9D-8DC9-0B6E5C713240Q40739584-6392E9A1-80FF-485A-860A-DB6584D456F2Q40951867-E99DEC10-3A76-4355-9ED2-26A83DD52FB9
P2860
A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
A large population study of sp ...... cations for antiviral therapy.
@ast
A large population study of sp ...... cations for antiviral therapy.
@en
type
label
A large population study of sp ...... cations for antiviral therapy.
@ast
A large population study of sp ...... cations for antiviral therapy.
@en
prefLabel
A large population study of sp ...... cations for antiviral therapy.
@ast
A large population study of sp ...... cations for antiviral therapy.
@en
P2093
P2860
P356
P1433
P1476
A large population study of sp ...... ications for antiviral therapy
@en
P2093
A O-O Chan
B C-Y Wong
D K-H Wong
P2860
P304
P356
10.1136/GUT.52.3.416
P407
P577
2003-03-01T00:00:00Z